Per the agreement, Lilly’s scientists and researchers will have access to Evidation’s data platform, helping them measure and understand patient behavior with regard to their health. They will have access to consented data derived from smartphones, connected sensors, wearables and the patient’s own voice.
Lilly’s research teams will also be able to use Evidation-built algorithms to process raw data for use in clinical studies or to create predictive models.
“Our initial collaborations with Lilly demonstrated that digital biomarkers can play a significant role in understanding individuals and disease, and we are excited to expand our collaboration,” said Christine Lemke, co-founder and president of Evidation.
More articles on health IT:
Teladoc faces class action lawsuit: 8 things to know
Google plans $1B New York City expansion
Vermont community hospital notifies 32,000 after data breach: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
